{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T11:45:25Z","timestamp":1771760725725,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijrobp.2018.07.2015","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T09:26:37Z","timestamp":1533547597000},"page":"1543-1550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing"],"prefix":"10.1016","volume":"102","author":[{"given":"Quentin","family":"Adams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolyn M.","family":"Hopfensperger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McGee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Caster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan T.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.07.2015_bib1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ijrobp.2009.08.048","article-title":"Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: Preliminary results of RTOG 0321","volume":"78","author":"Hsu","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib4","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/cncr.27911","article-title":"Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer","volume":"119","author":"Morris","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.brachy.2014.03.002","article-title":"High-dose-rate brachytherapy as monotherapy for prostate cancer","volume":"13","author":"Demanes","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jncimonographs\/lgs041","volume":"2012","author":"Wilt","year":"2012","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijrobp.2010.10.009","article-title":"Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer","volume":"82","author":"Mohammed","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijrobp.2005.02.015","volume":"63","author":"Akimoto","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ijrobp.2010.04.046","article-title":"Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer","volume":"80","author":"Morton","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib13","doi-asserted-by":"crossref","first-page":"051703","DOI":"10.1118\/1.4870441","article-title":"Interstitial rotating shield brachytherapy for prostate cancer","volume":"41","author":"Adams","year":"2014","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1088\/0031-9155\/58\/4\/957","article-title":"Gadolinium-153 as a brachytherapy isotope","volume":"58","author":"Enger","year":"2013","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1515\/raon-2017-0009","article-title":"Determination of dosimetric parameters for shielded 153Gd source in prostate cancer brachytherapy","volume":"51","author":"Ghorbani","year":"2017","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2017.06.008","article-title":"Multisource rotating shield brachytherapy apparatus for prostate cancer","volume":"99","author":"Dadkhah","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of-life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brachy.2011.05.003","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: Treatment description and preliminary results","volume":"11","author":"Prada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.radonc.2017.10.039","article-title":"Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial","volume":"126","author":"Gomez-Iturriaga","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2018.07.2015_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.apradiso.2017.09.028","article-title":"Practical aspects of 153Gd as a radioactive source for use in brachytherapy","volume":"130","author":"Famulari","year":"2017","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijrobp.2017.09.040","article-title":"Microdosimetric evaluation of current and alternative brachytherapy sources - A Geant4-DNA simulation study","volume":"100","author":"Famulari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acm2.12010","article-title":"Validation of rectal sparing throughout the course of proton therapy treatment in prostate cancer patients treated with SpaceOAR\u00ae","volume":"18","author":"Hedrick","year":"2017","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.urpr.2015.04.002","article-title":"Hydrogel spacer application technique, patient tolerance and impact on prostate intensity modulated radiation therapy: Results from a prospective, multicenter, pivotal randomized controlled trial","volume":"3","author":"Pieczonka","year":"2016","journal-title":"Urol Prac"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib29","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.radonc.2010.06.006","article-title":"Which \u03b1\/\u03b2 ratio and half-time of repair are useful for predicting outcomes in prostate cancer?","volume":"97","author":"Nickers","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib30","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0360-3016(03)01455-X","article-title":"How low is the alpha\/beta ratio for prostate cancer?","volume":"57","author":"Kal","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is \u03b1\/\u03b2 for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF02982830","article-title":"The mechanism of the induction by radiation of chromosome aberrations inTradescantia","volume":"44","author":"Lea","year":"1942","journal-title":"J Genet"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctro.2018.01.001","article-title":"The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"P\u00f6tter","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib34","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1118\/1.3426307","article-title":"Loss of radiobiological effect of imaging dose in image guided radiotherapy due to prolonged imaging-to-treatment times","volume":"37","author":"Flynn","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ijrobp.2009.05.054","article-title":"Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: Analysis of short- and medium-term toxicity and quality of life","volume":"77","author":"Morton","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An Analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijrobp.2009.05.046","article-title":"Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate","volume":"76","author":"Hermesse","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.2015_bib38","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1002\/mp.12598","article-title":"Direction modulated brachytherapy (DMBT) for treatment of cervical cancer: A planning study with 192Ir, 60Co, and 169Yb HDR sources","volume":"44","author":"Safigholi","year":"2017","journal-title":"Med Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618334837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618334837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T23:20:59Z","timestamp":1720480859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618334837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0360301618334837"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.2015","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.2015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}